A Message from
Danielle Menture

It is impossible to discuss 2020 without noting the tremendous challenges it brought to every aspect of our personal and professional lives.

For me, it was also my first full year working for Bristol Myers Squibb after nearly two decades with my previous employer. And for my new company, it was the first full year as a global biopharma industry leader after completing the acquisition of Celgene in 2019 that propelled the company to the Fortune 100.

Amid all this change, we were able to make significant progress on our ESG journey. Building upon the legacy of responsible business performance and passion for effecting positive change that made me proud to join the company, we took concrete steps forward. Having met or exceeded all five of our Sustainability 2020 Goals, we set bold new targets toward environmental and social goals.

We are building a strategic roadmap for ESG endorsed by our leadership team and Board of Directors. This serves as a holistic view of our risk profile whereby we can execute our growth, return on capital and our risk management over the long term. We recognize the importance of maintaining transparency in non-financial matters and are committed to continued improvement in reporting and stakeholder engagement on ESG topics.

Our 2021 reporting reflects the BMS corporate strategy and priority issues through frameworks such as SASB Standards, the CDP (formerly known as the Carbon Disclosure Project) and the Global Reporting Initiative (GRI), and through expanded direct disclosure of data on bms.com.